This article has been updated from an earlier version to correctly reflect the scope of a 2010 report cited by Sen. Lamar Alexander during the hearing that estimated the cost of FDA approval and clearance for medical devices.


NEW YORK (GenomeWeb) – As senators on the Committee on Health, Education, Labor, & Pensions mull legislative solutions to regulate lab-developed tests (LDTs) they have to try to advance a framework that facilitates rapid access to tests while ensuring patients can rely on the results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.